Discovery of a novel vulnerability in aggressive lymphoma could change future therapy

A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein cFLIP can be used to override the defenses of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. These defenses often cause treatments to be ineffective becau